MCL1 and acute myeloid leukemia: In this preclinical study, we assessed the HSP90 inhibitor PU-H71 in combination with the MCL1 inhibitor S63845 or the BCL2 inhibitor venetoclax in the treatment of acute myeloid leukemia and investigated the associated biomarkers of response.